Nov. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported third quarter 2024 financial results and ...

Seres Therapeutics Inc. (MCRB) on Wednesday reported third-quarter earnings of $88.8 million. The Cambridge, Massachusetts-based company said it had profit of 58 cents per share. Losses, adjusted to ...

Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24. Seres Therapeutics bulls ...

Seres Therapeutics (NASDAQ:MCRB) is scheduled to announce Q3 earnings results on Wednesday, November 13th, before market open ...

Salarius Pharmaceuticals Inc (SLRX) is expected to report for 3Q. Seres Therapeutics Inc (MCRB) is expected to report $-0.08 for 3Q. Sonida Senior Living Corp (SNDA) is expected to report $-0.18 for ...

Oppenheimer analyst Jeff Jones maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report) today and set a price target of ...

Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upgrading its current co-marketing ...

Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

At close: November 8 at 4:00 PM EST ...

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

Vertex Inc. (NASDAQ:VERX) ("Vertex” or the "Company”), a global provider of tax technology solutions, announced a new survey ...